Brand name · Oxymetazoline hydrochloride
Afrin Original Nasal: adverse event reports filed with FDA
682 reports list it as a suspect or interacting product, 2022–2026. Class: Vasoconstrictor.
- 682
- reports as suspect product
- 0% of all reports · about 152 a year
- 101
- reports, 12 months to June 2026
- 300 in the 12 months before
- 99.1%
- marked serious by the reporter
- 41.3% across the class
- 0.7%
- record death among outcomes, as reported
- 5 reports · not verified by FDA
Between January 2022 and June 2026, 682 adverse event reports received by FDA list the brand name Afrin Original Nasal (oxymetazoline hydrochloride) as a suspect or interacting product. Reports that mention it only as a concomitant medication (1) are left out of every figure here.
In the 12 months to June 2026, 101 reports listed it, down 66% from 300 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 152 reports a year and 0% of the 20,646,523 reports in the database, and 17% of the reports for the vasoconstrictor class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded drug dependence (89.3%), incorrect product administration duration (7.8%) and dyspnoea (6.7%). A report can list several reactions, so shares add to more than 100%; 64 different terms appear across these reports. Drug dependence is recorded in 89.3% of these reports, a larger share than in the median vasoconstrictor drug (44.6%).
99.1% of the reports are marked serious by the reporter (41.3% across the class); 0.7% record death among the outcomes and 1.5% record hospitalisation, as reported. 99.7% of the reports came from consumers, and the largest patient age group is 65 to 74 (1.3%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Afrin Original Nasal reports recording the termmedian drug in vasoconstrictor
- Drug dependencedependence on a medicine89.3%609
- Dyspnoeashortness of breath6.7%46
- Rebound nasal congestion5%34
- Rebound effect3.8%26
- Product use issuea problem in how the product was used3.4%23
- Sinus disorder2.8%19
- Inappropriate schedule of product administrationthe product was taken at the wrong times1.9%13
- Nasal congestiona blocked nose1.9%13
- Dependence1.8%12
- Epistaxisnosebleed1.8%12
- Nasal disorder1.6%11
- Nasal obstruction1.6%11
- Wrong technique in product usage processthe product was used in the wrong way1.5%10
- Drug ineffectivethe medicine did not work as expected1.3%9
- Maternal exposure during pregnancythe mother took the medicine during pregnancy0.9%6
- Feeling abnormalfeeling odd or not right0.7%5
- Nasal discomfort0.7%5
- Product use in unapproved indicationused for a purpose not on the label0.7%5
- Sinusitissinus infection0.7%5
- Anxietyanxiety0.6%4
- Blood pressure increaseda raised blood pressure reading0.6%4
- Hypertensionhigh blood pressure0.6%4
- Nasal operation0.6%4
- Paranasal sinus discomfort0.6%4
- Sinus operation0.6%4
- Anosmialoss of smell0.4%3
- Incorrect dose administeredthe wrong dose was given0.4%3
Top 30 of 64 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 4 drugs in the vasoconstrictor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 4,013 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Nasal congestion | 21 | 3.1% |
| Hypersensitivity | 17 | 2.5% |
| Nasopharyngitis | 5 | 0.7% |
| Sinus disorder | 5 | 0.7% |
| Epistaxis | 3 | 0.4% |
| Dyspnoea | 2 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 682 reports.
In context
| Measure | Afrin Original Nasal | Vasoconstrictor | All reports |
|---|---|---|---|
| Reports as suspect product | 682 | 4,013 | 20,646,523 |
| Share of that pool | — | 17% | 0% |
| Reports, latest 12 months | 101 | — | 1,332,454 |
| Marked serious | 99.1% | 41.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 7 | 8 | 91 |
| Hospitalisation recorded, per 1,000 reports | 15 | 25 | 213 |
| Consumer-filed share | 99.7% | 65.2% | 45.8% |
| Top term, share of reports | Drug dependence 89.3% | median 44.6% | 0.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the vasoconstrictor class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Upneeq | brand | 1,701 | 270 | 5.1% |
| Oxymetazoline hydrochloride | generic | 1,017 | 14 | 30.9% |
| Afrin Original | brand | 613 | 0 | 94.8% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Afrin Original Nasal reports
How many adverse event reports has FDA received for Afrin Original Nasal?
682 reports list Afrin Original Nasal as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 101 of them arrived in the latest 12 months. Another 1 list it only as a concomitant medication.
What reactions are recorded in Afrin Original Nasal reports?
drug dependence (89.3%), incorrect product administration duration (7.8%), dyspnoea (6.7%), rebound nasal congestion (5%) and rebound effect (3.8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Afrin Original Nasal was responsible.
How serious are the reports?
99.1% are marked serious by the reporter. Among the outcomes recorded, 0.7% of reports include death and 1.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (99.7%), physician (0.1%) and other health professional (0.1%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Afrin Original Nasal rising?
101 reports in the 12 months to June 2026, down 66% from 300 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Afrin Original Nasal was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Afrin Original Nasal?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Afrin Original Nasal as a suspect or interacting product; reports listing it only as a concomitant medication (1) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.